Phase 1Not yet recruiting
Use of Bone Marrow Stem Cells (MesenCell) for the Treatment of Patients With Chronic Graft-versus-host Disease
Use of Bone Marrow-Derived Mesenchymal Stem Cells (Mesencell) for the Treatment of Patients Undergoing Hematopoietic Progenitor Cell Transplantation Who Developed Refractory Moderate or Severe Chronic Graft-versus-Host Disease: A Phase I Clinical Trial
- Sponsor
- Pontifícia Universidade Católica do Paraná (Academic or other)
- Enrolment
- 20 planned
- Conditions
- Graft vs Host Disease; Mesenchymal Stem Cell Transplantation
- Interventions
- Mesenchymal Stem Cell Infusion
- Ages
- adults, older adults
- Registry
- NCT07826676, RBR-22jd7g5
Full record on ClinicalTrials.gov
From the registry
The purpose of this Phase I clinical trial is to evaluate the safety and potential treatment response of bone marrow-derived mesenchymal stem cells (MesenCell) in adult patients with moderate or severe chronic graft-versus-host disease (cGVHD) that is refractory to corticosteroid treatment. The main questions it seeks to answer are: * Is MesenCell infusion safe in patients with corticosteroid-refractory chronic graft-versus-host disease? * Can MesenCell treatment improve the clinical response and disease control in these patients? Participants will receive one to three intravenous infusions of MesenCell, according to the study protocol and be followed for 12 months after the last MesenCell infusion.
Primary outcomes
- Number of Participants With Treatment-Related Adverse Events
History
Study completion expected
Primary completion expected
Started
Registered
In the news
ResearchFight Aging! (opens Fight Aging! in a new tab)
37-study review finds mesenchymal stem cell microRNAs neuroprotective in Parkinson’s, Alzheimer’s and stroke models
In animal models, miR-133b, miR-146a, miR-17-92 and miR-223 reduced inflammation and apoptosis; targeted microRNA delivery improved motor and cognitive performance.
